Oxandrolone
- Atc Codes:A14AA08
- CAS Codes:53-39-4
- PHARMGKB ID:53-39-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Oxandrin, Oxandrolone.
Latin America
Mexico: Xtendrol.
Drug combinations
Chemistry
Oxandrolone: C~19~H~30~O~3~. Mw: 306.44. (1) 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5α,17β)-; (2) 17β-Hydroxy-17-methyl-2-oxa-5α-androstan-3-one. CAS-53-39-4 (1962).
Pharmacologic Category
Hormones and Synthetic Substitutes; Androgens. (ATC-Code: A14AA08).
Mechanism of action
Synthetic testosterone derivative with marked anabolic activity and relatively few androgenic effects. Produces retention of nitrogen, increases protein anabolism and amino acid utilization, and decreases urinary calcium concentrations. Increases lean body mass, body cell mass, and muscle strength. Increases bone mineral density and content. Inhibits protein catabolism induced by corticosteroids. Androgens stimulate production of erythrocytes, apparently by enhancing production of erythropoietin. Inhibits release of endogenous testosterone via feedback inhibition of pituitary luteinizing hormone. Large doses of androgens may suppress spermatogenesis.
Therapeutic use
Adjunctive therapy to promote weight gain. To offset protein catabolism with prolonged corticosteroid administration. Relief of bone pain associated with osteoporosis.
Pregnancy and lactiation implications
Masculinization of fetus reported. Excretion in breast milk unknown (not recommended in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to oxandrolone or any component of the formulation. Nephrosis. Carcinoma of breast or prostate. Hypercalcemia. Pregnancy.
Warnings and precautions
May cause blood lipid changes with increased risk of arteriosclerosis. Anabolic steroids may cause peliosis hepatis or liver cell tumors. Use with caution in breast cancer (may cause hypercalcemia by stimulating osteolysis), in COPD, in diabetes mellitus, and in conditions influenced by edema (e.g. cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention. Use caution with concomitant warfarin therapy, and in elderly patients (may be at greater risk for prostatic hyperplasia, fluid retention, and transaminase elevations). May accelerate bone maturation without producing compensatory gain in linear growth in children. May cause mild virilization in women. May suppress factors II, V, VII, and X. May increase prothrombin time. May decrease thyroxine-binding globulin and radioactive iodine uptake.